IFNG and breast carcinoma: The elicited CTLs demonstrate specific effector function, as measured by their capacity to kill breast cancer cells used for priming, to kill T2 cells pulsed with defined peptides derived from breast cancer antigens, and to secrete IFN-γ upon peptide exposure.